Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01659580 · ClinicalTrials.gov registry record · Phase 3
Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina
A Phase 3 study of Angina Pectoris, sponsored by Tasly Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,004
- Enrollment target
- 20
- Study locations
NCT01659580 is a Phase 3 study of Angina Pectoris that has completed, run by Tasly Pharmaceuticals. The registered enrollment target is 1,004 participants, above the 803-participant average among 9 other Angina Pectoris trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT01659580, a Phase 3 study of Angina Pectoris, has completed, sponsored by Tasly Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,004 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III study is designed as a double blind, randomized, multi-nation, multi-center, placebo controlled clinical research, which aims to evaluate the safety and efficacy of Dantonic® (T89) in patients with chronic stable angina pectoris.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG T89 high dose
- DRUG T89 Low dose
- DRUG Sanqi+Bingpian
Study Locations (20)
Florida
- Jacksonville Center for Clinical Research - Jacksonville
- Brevard Cardiovascular Research Associates - Merritt
- SouthCoast Research Center, Inc - Miami
- Molecular Imaging Research and Clinical Trials - Miami
- Integrity Clinical Trials - Miami
- NewPhase Clinical Trials, Inc. - Miami Beach
- Peninsula Research, Inc. - Ormond Beach
- Cardiovascular Center of Sarasota - Sarasota
- Jedidiah Clinical Research - Tampa
California
- Beaver Medical Clinic - Banning
- Foundation for Cardiovascular Medicine - La Jolla
- Precision Research Institute - National City
- Paradigm Clinical Research Institute, Inc. - Torrance
- Harbor-UCLA Medical Center - Torrance
Georgia
- Athens Heart Center - Athens
- Atlanta Clinical Research Center - Atlanta
- Ellipsis Research - Atlanta
Arkansas
- Cardiology and Medicine Clinic - Little Rock
Kentucky
- Central Cardiology - Campbellsville
Louisiana
- Alexandria Cardiology Clinic - Alexandria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,004 participants |
| Start Date | 2012-08 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01659580
The ClinicalTrials.gov registry entry for NCT01659580 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,004 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 803-participant average among 9 other Angina Pectoris trials with a reported enrollment target (25% higher). The listed sponsor is Tasly Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Angina Pectoris appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01659580 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT01659580 about?
NCT01659580 is a clinical study titled "Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina". This phase III study is designed as a double blind, randomized, multi-nation, multi-center, placebo controlled clinical research, which aims to evaluate the safety and efficacy of Dantonic® (T89) in patients with chronic stable angina pectoris.
What is the current status of trial NCT01659580?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,004 participants. The study started on 2012-08. Estimated completion is 2016-12.
What conditions does trial NCT01659580 study?
This clinical trial studies the following conditions: Angina Pectoris.
What interventions are being tested in trial NCT01659580?
The interventions under investigation include: Placebo (DRUG), T89 high dose (DRUG), T89 Low dose (DRUG), Sanqi+Bingpian (DRUG).
Who is sponsoring clinical trial NCT01659580?
This trial is sponsored by Tasly Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01659580 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angina Pectoris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
RECRUITING · Phase 2
-
Invest-CTO PCI Trial
ACTIVE NOT RECRUITING · NA
-
Comparing TR Band to Statseal in Conjunction With TR Band
COMPLETED · NA
-
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
COMPLETED
-
Coronary Obstruction Detection by Molecular Personalized Gene Expression (Corus CAD or ASGES)
COMPLETED
-
Collaborative Cardiac Care Project
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.